%0 Journal Article
%A Rudnicki, Stacy A
%A Al-Chalabi, Ammar
%A Andrews, Jinsy A
%A Chio, Adriano
%A Corcia, Philippe
%A Couratier, Philippe
%A Cudkowicz, Merit E
%A De Carvalho, Mamede
%A Genge, Angela
%A Hardiman, Orla
%A Heiman-Patterson, Terry
%A Henderson, Robert D
%A Ingre, Caroline
%A Johnston, Wendy
%A Ludolph, Albert
%A Maragakis, Nicholas J
%A Miller, Timothy M
%A Mora, Jesus S
%A Petri, Susanne
%A Simmons, Zachary
%A Van Den Berg, Leonard H
%A Zinman, Lorne
%A Herder, Katherine E
%A Kupfer, Stuart
%A Malik, Fady I
%A Meng, Lisa
%A Simkins, Tyrell J
%A Wei, Jenny
%A Wolff, Andrew A
%A Shefner, Jeremy M
%T Hospitalizations as an outcome measure in COURAGE-ALS.
%J Amyotrophic lateral sclerosis & frontotemporal degeneration
%V 26
%N 7-8
%@ 2167-8421
%C Abingdon
%I Taylor Francis Group
%M DZNE-2025-01179
%P 802 - 811
%D 2025
%X Objective: To describe the development of a methodology to characterize hospitalizations and their relationship to amyotrophic lateral sclerosis (ALS) and provide results using this process in a phase 3 trial of reldesemtiv in ALS. Methods: ALS clinical trialists assisted in developing a classification system to determine if a hospitalization was related to ALS (HR-ALS), unrelated (HU-ALS), or if the relationship was indeterminate (HI-ALS) and this was applied by the investigators to hospitalizations in COURAGE-ALS. Time to first hospitalization and number of hospitalizations were compared between those assigned reldesemtiv or placebo for up to 48 weeks. Demographic and clinical features were evaluated for prediction of hospitalization risk; this analysis was limited to those participants who completed the first 24-week double-blind placebo-controlled portion of the trial. Results: COURAGE-ALS terminated early due to futility. Time to first hospitalization was similar in the reldesemtiv compared to placebo arms as was the incidence, with 86 of the participants (17.6
%K Humans
%K Amyotrophic Lateral Sclerosis: drug therapy
%K Amyotrophic Lateral Sclerosis: therapy
%K Amyotrophic Lateral Sclerosis: diagnosis
%K Amyotrophic Lateral Sclerosis: epidemiology
%K Hospitalization: statistics & numerical data
%K Male
%K Female
%K Middle Aged
%K Double-Blind Method
%K Aged
%K Outcome Assessment, Health Care: methods
%K Amyotrophic lateral sclerosis (Other)
%K COVID-19 (Other)
%K fast skeletal muscle troponin activator (Other)
%K hospitalization (Other)
%K motor neuron disease (Other)
%K reldesemtiv (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:40503807
%R 10.1080/21678421.2025.2515907
%U https://pub.dzne.de/record/281786